Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review
Research To Practice | Oncology Videos · Dr. Neil Love
February 13, 202617m 19s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr Sagar Lonial, including the following topics:
- Phase 3 randomized study evaluating teclistamab and daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib for patients with relapsed/refractory (R/R) multiple myeloma (MM) (0:00)
- Management of belantamab mafodotin-associated ocular events with dose modifications guided by standard assessments (3:15)
- Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone for transplant-ineligible patients with newly diagnosed MM (8:00)
- Other investigational strategies for R/R MM (12:55)